X0306 4 2020-11-16 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001671870 Rivera Jose E C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, General Counsel Common Stock 2020-11-16 4 M 0 10000 6.83 A 52315 D Common Stock 2020-11-16 4 S 0 2020 33.75 D 50295 D Common Stock 2020-11-16 4 S 0 3595 34.51 D 46700 D Common Stock 2020-11-16 4 M 0 562 18.30 A 47262 D Common Stock 2020-11-16 4 S 0 414 35.00 D 46848 D Common Stock 2020-11-18 4 M 0 848 18.30 A 47696 D Common Stock 2020-11-18 4 S 0 624 35.00 D 47072 D Common Stock 262210 I See Footnote Stock Option (right to buy) 6.83 2020-11-16 4 M 0 10000 0.00 D 2026-02-02 Common Stock 10000 105117 D Stock Option (right to buy) 18.30 2020-11-16 4 M 0 562 0.00 D 2027-12-11 Common Stock 562 71938 D Stock Option (right to buy) 18.30 2020-11-18 4 M 0 848 0.00 D 2027-12-11 Common Stock 848 71090 D The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.08 to $34.03, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.09 to $34.86, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2020 at each separate price. Shares are held by Rivak Capital LLC ("Rivak"). Mr. Rivera is a member and the general manager of Rivak and has voting and dispositive power over these shares. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on February 3, 2020. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 52,864 shares as of November 16, 2020. /s/Jose Rivera 2020-11-18